Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tianyin Pharmaceutical wins Chinese approval for asthma drug
Tianyin said that Laonian Kechuan tablet is a traditional Chinese medicine drug that effectively treats asthma in people aged 60 or above. The company plans to launch Laonian
Tianyin said that Laonian Kechuan tablet is a traditional Chinese medicine drug that effectively treats asthma in people aged 60 or above. The company plans to launch Laonian
The submission is supported by data from the Phase III Flex study which demonstrated a significant increase in overall survival for patients receiving Erbitux in combination with a
Huperzine A is said to be a naturally occurring alkaloid found from the club moss Huperzia serrata that has been used for decades in China as a prescription
The study has indicated that Clonicel achieved statistical significance on the primary endpoint, which is based on the attention deficit hyperactivity disorder (ADHD) rating scale of 18 symptoms
The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients. Circassia
Pursuant to the agreement, BurnsAdler will act as Dor’s distributor of a named patient access program (NPAP) for orBec to patients suffering from acute gastrointestinal graft-versus-host disease in
XenoPort intends to initiate this two-week, multi-center, double-blind, placebo controlled trial in the fourth quarter of 2008. The primary objective of the study will be to evaluate the
In this newly created position, Mr Sheng will be responsible for directing neurobiology drug discovery efforts at Genentech and will oversee the department of neurobiology. He will report
The new regional headquarters will be double the size of its existing presence in Singapore and will be the home of the region’s largest clinical development organization. Quintiles’s
The final studies involved 150 animals that received single, repeated intra-muscular injections of PLX-PAD or a control substance then followed for up to three months post-injection. No adverse